Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of building a world of connection for people with hearing and balance disorders. Guidelines: https://bit.ly/3IzmNvU
View Top Employees from Decibel TherapeuticsWebsite | http://decibeltx.com |
Ticker | DBTX |
Revenue | $12 million |
Funding | $316.2 million |
Employees | 88 (88 on RocketReach) |
Founded | 2015 |
Address | 1325 Boylston Street Suite 500, Boston, Massachusetts 02215, US |
Phone | (617) 370-8701 |
Technologies |
JavaScript,
HTML,
PHP
+40 more
(view full list)
|
Industry | Biotechnology Research, Healthcare Software, Biotechnology, Software Development & Design, Science and Engineering, Software, Medical Device, Health Care, Therapeutics |
Web Rank | 4 Million |
Keywords | Decibel Therapeutics, Hearing Research Company Usa, Steven Holtzman, Decibel Company, Dicebel Theraputics Directory |
Competitors | Beam Therapeutics, Codiak BioSciences, Editas Medicine, Idera Pharmaceuticals, Sigilon Therapeutics, Inc. |
SIC | SIC Code 737 Companies, SIC Code 73 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 541511 Companies, NAICS Code 54 Companies, NAICS Code 5415 Companies, NAICS Code 54151 Companies |
Looking for a particular Decibel Therapeutics employee's phone or email?
The Decibel Therapeutics annual revenue was $12 million in 2024.
Jeffrey Schulz is the Vice President, Finance of Decibel Therapeutics.
88 people are employed at Decibel Therapeutics.
Decibel Therapeutics is based in Boston, Massachusetts.
The NAICS codes for Decibel Therapeutics are [541, 541511, 54, 5415, 54151].
The SIC codes for Decibel Therapeutics are [737, 73].